DRugwatch BlogRSS 2.0

DRugwatch Blog

Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).
Read more.
Posted on: 11/11/2014 9:36:25 AM | with 0 comments


Gideon HeapContributor: Gideon Heap

Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.

Read more.
Posted on: 11/7/2014 10:07:43 AM | with 0 comments


  Contributor: Conor Walsh

 This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

  • Risk and benefit of dual antiplatelet therapy (DAPT),
  • Anti-lipid therapy and prevention of coronary artery disease,
  • Treatment of structural heart disease
  • Drugs, devices and systems of care for ischemic heart disease.
Read more.
Posted on: 10/22/2014 5:22:24 PM | with 0 comments


Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs. Read more.
Posted on: 10/9/2014 1:33:46 PM | with 0 comments


Contributors: Kirsha Naicker and Dan Roberts

HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years. Read more.
Posted on: 10/8/2014 10:15:17 AM | with 0 comments


Contributor: Sehrish Rafique

Companies are now striving towards developing targeted therapies for advanced gastric cancer. Exploiting biomarkers is a dominant strategy and clinical data presented at the recent ESMO conference highlighted significant advances in the treatment of gastric cancer.
Read more.
Posted on: 10/7/2014 9:06:40 AM | with 0 comments


Contributor: Stefanie Hoffart

Between September 15 and 19, the European Association for the Study of Diabetes (EASD) meeting took place in Vienna, Austria, celebrating its 50th anniversary.
Read more.
Posted on: 10/1/2014 3:05:08 PM | with 0 comments


Contributors: Tim Blackstock and Stefanie Hoffart

Statins are one of the most commonly prescribed drugs, and Pfizer’s Lipitor (atorvastatin) still holds the record for the highest peak sales of any prescription drug. The general consensus of thought leaders in the field of lipid disorders and CVD prevention is that the benefits of statins outweigh the risks, although this applies more for secondary prevention that primary prevention.
Read more.
Posted on: 8/18/2014 1:07:35 PM | with 0 comments


Contributor: Chris Lewis

Faced with the onslaught of high-cost specialty drugs—a reality brought to the fore by the high-priced hepatitis C drug Sovaldi—many plan sponsors no doubt heaved a sigh of relief at the first U.S. filing for approval of a biosimilar last month. Read more.
Posted on: 8/13/2014 11:23:09 AM | with 0 comments


Contributor: Sangha Mitra

Last month, AstraZeneca took a major step to build up its respiratory franchise by striking a deal for the commercial rights to Almirall’s respiratory portfolio. The transaction, which is expected to complete by the end of 2014, could be worth up to $2.1 billion. It comprises an initial upfront payment of $875 million to Almirall and up to $1.22 billion in additional payments tied to performance, both regulatory and commercial, milestones.
Read more.
Posted on: 8/12/2014 4:17:19 PM | with 0 comments


Displaying results 1-10 (of 163)
 |<  < 1 2 3 4 5 6 7 8 9 10  >  >| 

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
Pfizer Increases Enrollment by 40% in the SPIRE Cardiovascular Outcomes Trials for PCSK9 Inhibitor Bococizumab
Post date:
11/11/2014 9:36:25 AM
Post Summary:
Gideon HeapGideon HeapContributors: Tim Blackstock and Conor Walsh

The latest news from the battle of the PCSK9 inhibitors is that Pfizer has increased enrollment by approximately 40% in its SPIRE-1 and SPIRE-2 cardiovascular outcomes trials (CVOTs).

Post title:
Obesity Week 2014 - Belviq gets the combination treatment
Post date:
11/7/2014 10:07:43 AM
Post Summary:
Gideon HeapContributor: Gideon Heap

Eisai has released results of a trial in which good old phentermine was added to the company’s obesity treatment, Belviq (lorcaserin). The primary endpoint for the trial was to discover if the combination increased the risk of patients having serotonergic adverse events (bad) after 12 weeks. It didn’t (good). However, twice as many patients (10.1%) on the combo dropped out due adverse events compared with Belviq alone.


Post title:
What’s going to be Hot at the 2014 AHA Scientific Sessions?
Post date:
10/22/2014 5:22:24 PM
Post Summary:
  Contributor: Conor Walsh

 This year’s line-up of Late-Breaking Clinical Trial sessions looks very interesting; with many trials having the   potential to significantly impact clinical practice. The trial results will be presented over four days in separate sessions focusing on:

  • Risk and benefit of dual antiplatelet therapy (DAPT),
  • Anti-lipid therapy and prevention of coronary artery disease,
  • Treatment of structural heart disease
  • Drugs, devices and systems of care for ischemic heart disease.

Post title:
Advancing the Treatment of TKI-refractory NSCLC
Post date:
10/9/2014 1:33:46 PM
Post Summary:
Contributor: Orestis Mavroudis-Chocholis

NSCLC is considered by many to be the poster child for personalized medicine in oncology. The approval of TKIs for the treatment of EGFR-mutation-positive and ALK-translocation-positive NSCLC patients has redefined the NSCLC treatment algorithm and developers are now in fierce competition to be the first to market novel, more efficacious and better tolerated TKIs which can be used as follow-on treatment options or replacements for currently approved front-line TKIs.

Post title:
Realizing the Potential of HPV-associated Cancer Prevention
Post date:
10/8/2014 10:15:17 AM
Post Summary:
Contributors: Kirsha Naicker and Dan Roberts

HPV vaccinations were voted by ASCO this year to be one of the top five advances in modern oncology in the past 50 years.

Decision Resources Group brands include: